Akeso, Inc. (HK:9926) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The phase II study “A Multicenter, Open Label Phase II Clinical Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate to Severe Atopic Dermatitis” aims to test how well Akeso’s AK120 works and how safe it is. The focus is on patients with moderate to severe atopic dermatitis, a fast‑growing segment in the global dermatology market.
AK120 is an injected drug designed to reduce skin inflammation and itching in atopic dermatitis. It is given under the skin, with an adjusted starting dose for patients already using JAK inhibitor drugs, and then continued every two weeks for several months.
The trial uses a single treatment group, so all enrolled patients receive AK120 rather than being split into drug and placebo arms. The design is open label and non‑blinded, meaning both doctors and patients know they are getting AK120, and the main goal is to assess treatment benefit and side effects in real‑world‑like use.
The study was first submitted on November 14, 2024, reflecting Akeso’s push to expand beyond oncology into immunology. The most recent update on March 16, 2026, confirms that the trial has reached a “completed” status, clearing a key step toward planning larger pivotal studies or partnership talks.
For investors, a completed phase II study in atopic dermatitis broadens Akeso’s pipeline beyond its core oncology assets and may support a higher valuation if data show strong symptom relief and clean safety. The update also positions Akeso in a competitive field with players like Sanofi, Regeneron, and AbbVie, and any positive read‑through could lift sentiment around 9926 while sharpening focus on future readouts and licensing potential.
The AK120 atopic dermatitis phase II study is now completed and recently updated, with further details available on the ClinicalTrials.gov portal.
To learn more about HK:9926’s potential, visit the Akeso, Inc. drug pipeline page.